Novo Nordisk A/S (NYSE:NVO) Shares Sold by Wilkinson Global Asset Management LLC

Wilkinson Global Asset Management LLC reduced its stake in Novo Nordisk A/S (NYSE:NVO) by 11.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,980 shares of the company’s stock after selling 400 shares during the period. Wilkinson Global Asset Management LLC’s holdings in Novo Nordisk A/S were worth $256,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. New Century Financial Group LLC lifted its holdings in shares of Novo Nordisk A/S by 12.9% in the 3rd quarter. New Century Financial Group LLC now owns 1,954 shares of the company’s stock worth $233,000 after acquiring an additional 224 shares during the last quarter. Cyndeo Wealth Partners LLC lifted its stake in Novo Nordisk A/S by 12.8% during the third quarter. Cyndeo Wealth Partners LLC now owns 3,671 shares of the company’s stock worth $437,000 after purchasing an additional 418 shares in the last quarter. OLD National Bancorp IN lifted its stake in Novo Nordisk A/S by 30.5% during the third quarter. OLD National Bancorp IN now owns 4,399 shares of the company’s stock worth $524,000 after purchasing an additional 1,027 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in shares of Novo Nordisk A/S by 30.5% during the third quarter. Allspring Global Investments Holdings LLC now owns 427,785 shares of the company’s stock worth $50,936,000 after buying an additional 99,945 shares during the period. Finally, Whittier Trust Co. grew its stake in shares of Novo Nordisk A/S by 2.5% in the third quarter. Whittier Trust Co. now owns 45,796 shares of the company’s stock valued at $5,453,000 after buying an additional 1,115 shares in the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms recently issued reports on NVO. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research report on Wednesday, February 12th. They set an “equal weight” rating on the stock. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $82.44 on Wednesday. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The firm’s fifty day simple moving average is $87.45 and its 200-day simple moving average is $108.84. The firm has a market capitalization of $369.97 billion, a price-to-earnings ratio of 25.06, a PEG ratio of 0.84 and a beta of 0.45. Novo Nordisk A/S has a twelve month low of $77.82 and a twelve month high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Equities analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.7874 per share. The ex-dividend date is Monday, March 31st. This represents a yield of 1.2%. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 21.88%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.